Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Live Nation Entertainment, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $43.01B). The key difference: Live Nation Entertainment, Inc. is far larger — about 4.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | LYV | |
|---|---|---|
Market Cap | $9.39B | $43.01B |
Sector | Health | Industrials |
52-Week High | $356.25 | $186.59 |
52-Week Low | $241.71 | $125.61 |
Enterprise Value | $9.14B | $45.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Live Nation (LYV) trades at $180.66, down 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $209.54. The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by strong concert demand. However, valuation metrics like a P/E of 117.49 and a P/B of 511.19 appear elevated, while net income margin remains thin at 0.51% for 2025.
The outlook is supported by robust fan attendance and raised full-year expectations, but risks include high debt levels, legal uncertainties, and cost pressures. With 87% of analysts rating it a buy, the stock offers growth potential contingent on execution amid competitive and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
